Background: Physiological PSMA expression in the cells of the proximal renal tubules and
consecutive radiopharmaceutical binding and retention could potentially lead to radioligand …

MAG3 scintigraphy with determination of split renal function (SRF) is a standard procedure
in patients with metastasized castration-resistant prostate carcinoma (mCRPC) undergoing …

The aim of this study was to assess the safety, tolerability, and effects on renal function as
well as therapeutic efficacy of prostate-specific membrane antigen (PSMA)–targeted …

Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy with 177 Lu-
PSMA-617 has shown promising results in patients with metastasized castration-resistant …

Background:[177Lu] Lu-PSMA-617 radioligand therapy (PSMA-RLT) could affect kidney and
salivary gland functions in metastatic castration-resistant prostate cancer (mCRPC) patients …

Purpose Prostate-specific membrane antigen (PSMA) is present in the proximal tubule cells
of the kidneys. This results in high renal tracer uptake in PSMA-PET, which may contain …

Simple Summary Radioligand therapy (RLT) targeting prostate-specific membrane antigen
(PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate …

Background Prostate‐specific membrane antigen (PSMA)‐targeted radioligand therapy
(RLT) may be associated with renal toxicity. We aimed to identify predictive parameters for …

Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy
of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long …

Abstract 177 Lu-PSMA-617 radioligand therapy (RLT) has evolved as a suitable alternative
to existing therapeutic options in patients with metastatic castration-resistant prostate cancer …